Abstract:The porcine reproductive and respiratory syndrome viruses (PRRSV) led to a global panzootic and huge economical losses to the pork industry. PRRSV targets the scavenger receptor CD163 for productive infection. However, currently no effective treatment is available to control the spread of this disease. Using bimolecular fluorescence complementation (BiFC) assays, we screened a set of small molecules potentially targeting the scavenger receptor cysteine-rich domain 5 (SRCR5) of CD163. We found that the assay examining protein-protein interactions (PPI) between PRRSV glycoprotein 4 (GP4) and the CD163-SRCR5 domain mainly identifies compounds that potently inhibit PRRSV infection, while examining the PPI between PRRSV-GP2a and the SRCR5 domain maximized the identification of positive compounds, including additional ones with various antiviral capabilities. These positive compounds significantly inhibited both types 1 and 2 PRRSV infection of porcine alveolar macrophages. We confirmed that the highly active compounds physically bind to the CD163-SRCR5 protein, with dissociation constant (KD) values ranging from 28 to 39 μM. Structure-activity-relationship (SAR) analysis revealed that although both the 3-(morpholinosulfonyl)anilino and benzenesulfonamide moieties in these compounds are critical for the potency to inhibit PRRSV infection, the morpholinosulfonyl group can be replaced by chlorine substituents without significant loss of antiviral potency. Our study established a system for throughput screening of natural or synthetic compounds highly effective on blocking of PRRSV infection and shed light on further SAR modification of these compounds. IMPORTANCE Porcine reproductive and respiratory syndrome virus (PRRSV) causes significant economic losses to the swine industry worldwide. Current vaccines cannot provide cross protection against different strains, and there are no effective treatments available to hamper the spread of this disease. In this study, we identified a group of new small molecules that can inhibit the PRRSV interaction with its specific receptor CD163 and dramatically block the infection of both types 1 and type 2 PRRSVs to host cells. We also demonstrated the physical association of these compounds with the SRCR5 domain of CD163. In addition, molecular docking and structure-activity relationship analyses provided new insights for the CD163/PRRSV glycoprotein interaction and further improvement of these compounds against PRRSV infection.

A CDR-based approach to generate covalent inhibitory antibody for human rhinovirus protease

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

A Combinatorial Strategy for HRV 3C Protease Engineering to Achieve the N-terminal Free Cleavage

Rational Design of Antibody Protease Inhibitors.

De novo design of covalent bonding peptides for target protein

Identification of epidermal growth factor receptor-tyrosine kinase inhibitor targeting the VP1 pocket of human rhinovirus

Computational Characterization and Design of SARS Coronavirus Receptor Recognition and Antibody Neutralization.

Identification of Human Single-Domain Antibodies Against SARS-CoV-2.

Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors

Structure-guided mutations in CDRs for enhancing the affinity of neutralizing SARS-CoV-2 nanobody

Computational Design and Engineering of Self-Assembling Multivalent Microproteins with Therapeutic Potential Against SARS-CoV-2

Structure-guided Affinity Maturation of a Novel Human Antibody Targeting the SARS-CoV-2 Nucleocapsid Protein

A Novel Designed Single Domain Antibody on 3-D Structure of Ricin A Chain Remarkably Blocked Ricin-Induced Cytotoxicity

Identification of highly selective covalent inhibitors by phage display

Bicyclic Peptide-Enhanced Covalent Inhibitor of SARS-CoV-2 3CL Protease

Covalent Bonding Aptamer with Enhanced SARS-CoV-2 RBD-ACE2 Blocking and Pseudovirus Neutralization Activities

Designing and bioengineering of CDRs with higher affinity against receptor-binding domain (RBD) of SARS-CoV-2 Omicron variant

Design and bioassay of non-peptidic inhibitors of SARS coronavirus 3C-like proteinase

Acrylamide fragment inhibitors that induce unprecedented conformational distortions in enterovirus 71 3C and SARS-CoV-2 main protease

Identification of New Compounds against PRRSV Infection by Directly Targeting CD163

Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis